PHI Therapeutics Bacteriophage Eczema Patent Granted
Summary
The USPTO granted Patent US12605416B2 to PHI THERAPEUTICS, INC. on April 21, 2026, covering therapeutic compositions comprising bacteriophage and colloidal oatmeal for the treatment of skin diseases and conditions including eczema. The patent contains 17 claims classified under CPC A61K 35/76.
What changed
PHI THERAPEUTICS, INC. received a new patent grant (US12605416B2) from the USPTO for therapeutic compositions using bacteriophage and colloidal oatmeal to treat eczema and other skin conditions. The patent contains 17 claims and is classified under CPC code A61K 35/76. The filing date was December 27, 2024, with application number 19003326.
For pharmaceutical companies and manufacturers developing bacteriophage-based dermatological treatments, this grant signals that PHI THERAPEUTICS holds exclusive rights to this composition-of-matter approach. Competitors pursuing similar formulations may need to explore licensing arrangements or design-around strategies to avoid infringement.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compositions and methods for the treatment of skin diseases and conditions including eczema
Grant US12605416B2 Kind: B2 Apr 21, 2026
Assignee
PHI THERAPEUTICS, INC.
Inventors
Yug Varma, Elijah Horwitz
Abstract
Disclosed herein are therapeutic compositions comprising bacteriophage and colloidal oatmeal, and methods of using the compositions for the treatment of skin diseases and conditions including eczema.
CPC Classifications
A61K 35/76
Filing Date
2024-12-27
Application No.
19003326
Claims
17
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.